Navigation Links
Genoptix, Inc. to Announce Second Quarter 2009 Financial Results
Date:7/9/2009

CARLSBAD, Calif., July 9 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today that it expects to report its financial results for the second quarter of 2009 after closing of the NASDAQ Global Market on Thursday, July 30, 2009.

A conference call hosted by President and CEO, Dr. Tina S. Nova, and other members of senior management will take place on the same day at 2:00pm PDT (5:00pm EDT) and will be webcast live on the Genoptix website.

To access the live conference call via phone, dial 866-770-7129 in the U.S. or Canada and 617-213-8067 for international callers. Please specify to the operator that you would like to join the "Genoptix Second Quarter 2009 Earnings Conference Call." The participant code for the call is 62327967. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, August 6, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 95869060.

The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, August 27, 2009.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix' highly trained hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix completed its initial public offering in November 2007 and has been profitable since the first quarter of that year. Genoptix is a member the S&P SmallCap 600 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Any statements in this press release or that may be made on the Genoptix conference call about expectations, beliefs, plans, objectives, assumptions or future events, or future performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties that Genoptix faces, please refer to the "Risk Factors" section in the Company's most recent Annual Report on Form 10-K, as well as other subsequent filings with the Securities and Exchange Commission. Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix, Inc. to Announce First Quarter 2009 Financial Results
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix, Inc. Announces Pricing for Initial Public Offering
4. Carriage Services Announces Second Quarter Earnings Release and Conference Call Schedule
5. ONRAD Announces New PACS Application Service Provider Model
6. Duane Reade Holdings, Inc. Announces Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures
7. MedClean Technologies Announces Results of Private Exchange Offer
8. Universal Health Services, Inc. Announces Daniel B. Silvers Appointed to Board of Directors
9. Nuvilex, Inc. Announces Business Update Conference Call
10. B-Line Medical(R) and Mentice, Inc. Announce Data Integration Partnership
11. Tiger Schulmanns Mixed Martial Arts Announces Winners of 2009 90-Day Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon ... this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, the San Francisco Bay ... post about women’s hair loss. Although hair transplant procedures can be seen as more ... or genetics can be two reasons a woman may see her hair thinning. , ...
(Date:3/28/2017)... ... 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. ... that his parents and teachers had asked of him that he had neglected to do, ... defy the Almighty Creator. There were some who would have felt themselves to be special ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. ... smile makeovers without requiring a referral. Trimble Dental offers a variety of ... dentistry and dental implants. Whether patients have discolored, crooked or missing teeth in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... to the OSEHRA popHealth Community in 2014. It is the culmination ... the Developer Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 ... attention to these four stocks: The Medicines Co. ... Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. ... in the Generic Drugs space which is governed ... The key growth drivers for the industry are wholesalers, ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/27/2017)... SINGAPORE , March 27, 2017 ... a digital health and data analytics company, signed ... collaborations for improving healthcare delivery in the region. ... Institute for Global Health Research and Technology (BIGHEART) ... relationship on several topics related to healthcare IT ...
Breaking Medicine Technology: